Their common biological targets were von Hippel–Lindau (VHL)/hypoxia inducible factor/VEGF pathway to inhibit angiogenesis, and Raf/MEK/ERK and PI3K/Akt/mTOR pathways to inhibit cancer cell proliferation. This evidence concerns the gene AKT1 and cancer.